US 11,998,027 B2
Polypeptide for hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof as well as a polypeptide containing an additive, use of same as well as a process
Sebastian Fruhauf, Neulengbach (AT); Michaela Thamhesl, Vienna (AT); Martin Pfeffer, Tulln (AT); Dieter Moll, Stockerau (AT); Gerd Schatzmayr, Tulln (AT); and Eva Maria Binder, Tulln (AT)
Assigned to ERBER AKTIENGESELLSCHAFT, Traismauer (AT)
Filed by Erber Aktiengesellschaft, Getzersdorf bei Traismauer (AT)
Filed on Jun. 1, 2022, as Appl. No. 17/829,416.
Application 17/829,416 is a division of application No. 17/555,731, filed on Dec. 20, 2021, granted, now 11,910,807.
Application 17/555,731 is a division of application No. 16/934,179, filed on Jul. 21, 2020, granted, now 11,324,235, issued on May 10, 2022.
Application 16/934,179 is a division of application No. 16/161,266, filed on Oct. 16, 2018, granted, now 10,779,556, issued on Sep. 22, 2022.
Application 16/161,266 is a division of application No. 15/054,232, filed on Feb. 26, 2016, granted, now 10,076,125, issued on Sep. 18, 2018.
Application 15/054,232 is a continuation of application No. 14/914,671, granted, now 10,149,489, issued on Dec. 11, 2018, previously published as PCT/AT2014/000164, filed on Aug. 27, 2014.
Claims priority of application No. A 667/2013 (AT), filed on Aug. 28, 2013.
Prior Publication US 2022/0322701 A1, Oct. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A23K 10/14 (2016.01); A23K 50/30 (2016.01); A23K 50/75 (2016.01); A23K 50/80 (2016.01); A23L 3/3571 (2006.01); C12N 9/14 (2006.01); C12N 9/18 (2006.01)
CPC A23K 10/14 (2016.05) [A23K 50/30 (2016.05); A23K 50/75 (2016.05); A23K 50/80 (2016.05); A23L 3/3571 (2013.01); C12N 9/14 (2013.01); C12N 9/18 (2013.01); C12Y 301/01 (2013.01); A23V 2002/00 (2013.01); Y02A 40/818 (2018.01)] 11 Claims
 
1. A method for hydrolytic cleavage of zearalenone or at least one zearalenone derivative selected from the group of α-ZEL ((2E,7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]-octadeca-1(18),2,14,16-tetraen-13-one), β-ZEL (2E,7S,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-13-one), α-ZAL ((7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),14,16-trien-13-one), β-ZAL ((7S,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one), Z14G ((2E,11S)-15-hydroxy-11-methyl-17-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydropyran-2-yl]oxy-12-oxabicyclo[12.4.0]octadeca 1(18)2,14,16-tetraene-7,13-dione), Z14S ([(2E,11S)-15-hydroxy-11-methyl-7,13-dioxo-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-17-yl] hydrogen sulfate) and ZAN ((11S)-15,17-dihydroxy-11-methyl-12-oxabicyclo-[12.4.0]octadeca-1(18),14,16-triene-7,13-dione), wherein the zearalenone or at least one zearalenone derivative is/are hydrolyzed by a polypeptide having the amino acid sequence of SEQ ID NO: 12 or a functional variant thereof, wherein the sequence identity between the functional variant and the amino acid sequence of SEQ ID NO: 12 is at least 70%; and wherein the polypeptide having the amino acid sequence of SEQ ID NO: 12 or the functional variant thereof has an α,β-hydrolase structure, which is suitable for oxygen-independent and cofactor-free hydrolytic cleavage of the ester group of zearalenone or at least one zearalenone derivative selected from the group of α-ZEL ((2E,7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]-octadeca-1(18),2,14,16-tetraen-13-one), β-ZEL (2E,7S,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-13-one), α-ZAL ((7R,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(18),14,16-trien-13-one), β-ZAL ((7S,11S)-7,15,17-trihydroxy-11-methyl-12-oxabicyclo[12.4.0]octadeca-1(14),15,17-trien-13-one), Z14G ((2E,11S)-15-hydroxy-11-methyl-17-[(3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydropyran-2-yl]oxy-12-oxabicyclo[12.4.0]octadeca 1(18)2,14,16-tetraene-7,13-dione), Z14S ([(2E,11S)-15-hydroxy-11-methyl-7,13-dioxo-12-oxabicyclo[12.4.0]octadeca-1(18),2,14,16-tetraen-17-yl] hydrogen sulfate) and ZAN ((11S)-15,17-dihydroxy-11-methyl-12-oxabicyclo-[12.4.0]octadeca-1(18),14,16-triene-7,13-dione).